EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment

Emerson Achari, Farah Ahmady-Nield, Amit Sharma iD, Ingo G H Schmidt-Wolf, Jarek Maciaczyk, Rodney B Luwor, Adrian A Achuthan

Immunology & Cell Biology · 2026-08 · 104 (7) · 711-728

DOI: 10.1111/imcb.70144 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunology & Cell Biology, online erschienen am 03.07.2026. Verfasst von Emerson Achari und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Glioblastoma, Drug Resistance, Neoplasm, Brain Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High‐grade central nervous system cancers incur a significant burden of care on society. The combination of therapeutic resistance and high mortality makes it both a challenging target and a devastating diagnosis. Of these, one in two is characterized as glioblastoma (GBM) with a median survival rate of only 13.5 months with the current standard of therapy. Modern interventions, such as PD‐1 and CTLA‐4 checkpoint inhibition and autologous CAR T cell delivery, remain stymied by both the difficult nature of drug delivery to the brain and the inherent immunosuppressive tumor microenvironment. However, recent advances in the characterization of GBM have unveiled promising new therapeutic avenues aiming to target and eliminate the tumor. In this review, we summarize the mechanisms through which GBM is initiated, localized, and eludes therapy responses and provide an update on recent advances made within this therapeutic space to overcome GBM‐mediated immunosuppression. We also discuss the challenges with current and next generational treatment strategies before finally exploring the landscape of potential future therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaDrug Resistance, NeoplasmBrain NeoplasmsHumansAnimalsTumor MicroenvironmentImmunotherapy

Stichwörter der Autor:innen

glioblastomahypoxiaimmunosuppressionimmunotherapytumor microenvironment

Autor:innen und Institutionen

  • Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia.
  • Fiona Elsey Cancer Research Institute, Ballarat, Victoria, Australia.
  • Federation University Australia, Ballarat, Victoria, Australia.
  • Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany.
  • Department of Neurosurgery, University Hospital Bonn, Bonn, Germany.
  • Department of Surgery, Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia.

ORCID-Profile: Amit Sharma

Zitieren

APA

Achari, E., Ahmady-Nield, F., Sharma, A., Schmidt-Wolf, I. G. H., Maciaczyk, J., Luwor, R. B., & Achuthan, A. A. (2026). Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment. Immunology & Cell Biology, 104(7), 711-728. https://doi.org/10.1111/imcb.70144

Vancouver

Achari E, Ahmady-Nield F, Sharma A, Schmidt-Wolf IGH, Maciaczyk J, Luwor RB, et al. Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment. Immunology & Cell Biology. 2026;104(7):711-728. doi:10.1111/imcb.70144

BibTeX
@article{Achari2026,
  author = {Achari, Emerson and Ahmady-Nield, Farah and Sharma, Amit and Schmidt-Wolf, Ingo G H and Maciaczyk, Jarek and Luwor, Rodney B and Achuthan, Adrian A},
  title = {Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment},
  journal = {Immunology & Cell Biology},
  year = {2026},
  volume = {104},
  number = {7},
  pages = {711--728},
  doi = {10.1111/imcb.70144}
}
Kostenlos starten →